Quality Institute Advisory Group

Leaders in the science of quality and public health guide the Quality Institute’s research agenda.

Advisory Group Members


deb-autor-headshot.jpgDeb Autor
Head of Strategic Global Quality & Regulatory Policy, Mylan
USP Advisory Group

Deb Autor is Head of Strategic Global Quality and Regulatory Policy at Mylan, one of the largest generics and specialty pharmaceutical companies in the world. In this role, Ms. Autor represents Mylan’s diverse and complex operations to government officials globally and advises Mylan’s most senior leaders on how to navigate and influence the regulatory landscape. Previously, as Mylan’s Global Head of Quality, Ms. Autor managed thousands of personnel around the world, driving quality improvements across scores of manufacturing sites.

Prior to joining Mylan in 2013, Ms. Autor served for 12 years at the U.S. Food and Drug Administration (FDA), most recently as Deputy Commissioner for Global Regulatory Operations and Policy, where she supervised more than 4,000 employees in FDA’s Office of Regulatory Affairs and Office of International Programs in their efforts to confront the challenges of globalization and import safety. She also served for five years as Director of the Office of Compliance of FDA’s Center for Drug Evaluation and Research, where she led policymaking and enforcement for key programs for drugs, including current good manufacturing practices, human subject protection, and marketed unapproved drugs.


thierry-bourquin-headshot.jpgThierry Bourquin
Senior Vice-President Global Chief Quality Officer, Sanofi
USP Advisory Group

Thierry Bourquin has been Senior Vice-President Global Chief Quality Officer at Sanofi since 2009. He joined Sanofi in 2001 as Head of Industrial Quality and Compliance. In 2004, he took the lead of Global Quality Industrial Operations for Sanofi. After serving in Hospitals and at Paris University, he held several positions in Quality Control, Quality Assurance, Analytical Development and Manufacturing in the pharmaceutical industry (Pfizer, Cooper, RPR, Aventis).

During more than 15 years, Mr. Bourquin has been a member of the French Pharmacopoeia Commission and expert in different groups. At the European level, he was expert of the European Pharmacopoeia and member of the Quality Ad Hoc Group of EFPIA. He also served as Chairman of the Quality Committee of LEEM, French Association of Pharmaceutical Industry. A pharmacist, Mr. Bourquin, graduated with degrees in biology and drug product control, is member of the French National Academy of Pharmacy.


Susan-Hershenson-headshot.jpgSusan Hershenson, Ph.D.
Deputy Director, Chemistry, Manufacturing and Controls, The Bill and Melinda Gates Foundation
USP Advisory Group

Susan Hershenson, Ph.D., has more than 25 years of experience in drug development. She joined the Bill and Melinda Gates Foundation in 2013 as Deputy Director, Chemistry, Manufacturing, and Controls, where she works closely with the Foundation’s strategy teams and partners to provide technical expertise and strategic guidance for the therapeutics projects.

Prior to joining the foundation, Dr. Hershenson founded Pharmaceutical Transformations LLC, a consulting service for the pharmaceutical, biotechnology, drug delivery, and related industries. Before starting her own practice, she served in a variety of roles in the biopharmaceutical industry, including most recently Vice President of Pharmaceutical and Device Development at Genentech and Vice President of Pharmaceutics at Amgen.


Ramanan-Laxminara-headshoyan-headshot.jpgRamanan Laxminarayan, Ph.D., M.P.H.
Director and Senior Fellow, The Center for Disease Dynamics, Economics & Policy
USP Advisory Group

Ramanan Laxminarayan, Ph.D., M.P.H., is director and senior fellow at the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C., and a senior research scholar and lecturer at the Princeton Environmental Institute at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Kwazulu Natal. Dr. Laxminarayan is a co-founder of HealthCubed, which works to improve access to healthcare and diagnostics.

Since 1995, Dr. Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource. His work encompasses extensive peer-reviewed research, public outreach, and direct engagement in eleven countries in Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a TED talk that has been widely viewed) and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policymakers worldwide and to the United Nations General Assembly in September 2016.


John-Lim-headshot.jpgJohn Lim, M.D., M.S., S.M.
Executive Director, Duke-NUS CoRE
USP Advisory Group

John Lim, M.D., M.S., S.M., serves as Executive Director of the Centre of Regulatory Excellence (CoRE) at the Duke-National University of Singapore Medical School (Duke-NUS). He is also Deputy Director of Medical Services at the Ministry of Health Singapore.

Dr. Lim is a Specialist in Public Health Medicine, a Fellow of the Singapore Academy of Medicine, Professor of Practice at Duke-NUS, and Adjunct Associate Professor at the NUS Saw Swee Hock School of Public Health. He is also Chairman of the Singapore Clinical Research Institute, a national Academic Research Organization under MOH Holdings, Singapore. He previously served as Chief Executive Officer of Singapore’s Health Sciences Authority.


Gail-Wilensky-headshot.jpgGail Wilensky, Ph.D.
Senior Fellow, Project HOPE
USP Advisory Group

Gail R. Wilensky, Ph.D. joined Project HOPE in 1993. She is an economist and Senior fellow at Project HOPE. Prior to joining Project HOPE, Dr. Wilensky directed the Medicare and Medicaid programs and served in the White House as a senior advisor on health and welfare issues to President George H.W. Bush. She was also the first chair of the Medicare Payment Advisory Commission. Her expertise is on strategies to reform health care in the United States, with particular emphasis on Medicare, comparative effectiveness research and military health care.

Dr. Wilensky testifies frequently before Congressional committees, serves as an adviser to members of Congress and other elected officials and speaks nationally and internationally. She received a bachelor’s degree in psychology and a Ph.D. in economics from the University of Michigan.

USP Board of Trustees Sponsor


susa-winckler-headshot.jpgSusan C. Winckler, J.D., FAPhA
President, Leavitt Partners Consulting
USP Board Sponsor

Susan Winckler, J.D., is the President of Leavitt Partners Consulting and Chief Risk Management Officer of Leavitt Partners. Ms. Winckler leads the 100+-person LP Consulting team, individually advises clients on how to succeed in the evolving value-driven health care economy, and leads new product development to ensure clients have the latest intelligence and tools needed for strategic planning and positioning of organizational assets. She also oversees the firm’s corporate compliance program, conflict of interest procedures, and legal record management.

A pharmacist and attorney by training, Ms. Winckler is the former Chief of the Staff for the U.S. Food and Drug Administration within the Department of Health and Human Services, and former President and CEO of the Food and Drug Law Institute, a nonprofit organization based in Washington, D.C., which provides a marketplace for discussing food and drug law issues through conferences, publications, and member interaction.